[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-344953-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-344953-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","the-cervico-vaginal-dna-methylation-wid-qec-test-an-epigenetic-marker-associated-with-ovarian-cancer-in-the-absence-of-endometrial-and-cervical-cancer-short-report","The cervico-vaginal DNA methylation WID-qEC test - An epigenetic marker associated with ovarian cancer in the absence of endometrial and cervical cancer - Short report","","The DNA methylation-based WID-qEC test, using cervico-vaginal samples, detects endometrial and cervical cancers accurately, yet a subset of women tests positive without these malignancies. This study examined biological and clinical features linked to WID-qEC-positive cases, analyzing 1269 samples from women without endometrial or cervical cancer (healthy, benign gynecologic disease, and ovarian cancer groups). Among 80 positive results, 43 (54%) involved ovarian cancer, and positivity associated with ovarian cancer and more lifetime ovulatory cycles independent of age, menopause, hormone therapy, and family history. Findings suggest elevated ovarian cancer risk or presence; however, standalone PPV remained low in the general population, motivating two-step triage research concepts.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/the-cervico-vaginal-dna-methylation-wid-qec-test-an-epigenetic-marker-associated-with-ovarian-cancer-in-the-absence-of-endometrial-and-cervical-cancer-short-report/344953/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/the-cervico-vaginal-dna-methylation-wid-qec-test-an-epigenetic-marker-associated-with-ovarian-cancer-in-the-absence-of-endometrial-and-cervical-cancer-short-report/344953.png","ImageObject",300,407,{"name":42,"@type":43},"Aurora","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-15","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why was this study conducted on WID-qEC-positive women without endometrial or cervical cancer?","Question",{"text":63,"@type":64},"Because a small proportion of women test positive with WID-qEC despite having no endometrial or cervical cancers, prompting investigation of associated biological and clinical characteristics.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What samples and groups were analyzed in the study?",{"text":68,"@type":64},"The study analyzed 1269 cervico-vaginal samples from women without endometrial or cervical cancer, including healthy controls, women with benign gynecological conditions, and ovarian cancer cases.",{"name":70,"@type":61,"acceptedAnswer":71},"What factors were associated with WID-qEC positivity in the absence of endometrial or cervical cancer?",{"text":72,"@type":64},"WID-qEC positivity was associated with ovarian cancer and with a higher number of lifetime ovulatory cycles, and these associations were independent of age, menopausal status, hormone replacement therapy usage, and family history.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},344953,1790185563,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":107,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},4810365810221,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","DOI: 10.1002/ijc.70354  \nSHORT REPORT  \nInnovative Tools a n d M ethods  \nThe cervico-vaginal DNA methylation WID-qEC test: An epigenetic marker associated with ovarian cancer in the absence of endometrial and cervical cancer  \nElisa Redl 1,2  | Chiara Herzog 1,2  | Charlotte Vavourakis 1,2  |  \nJames Barrett 1,2  | Allison Jones 3 | Iona Evans 3 | Daniel Reisel 3 | Ranjit Manchanda 4,5,6 | Line Bjørge 7,8 | Michal Zikan 9,10 | David Cibula 10 | Twana Alkasalias 11,12 | Angelique Flöter Rådestad 11 |  \nKristina Gemzell-Danielsson 11 | Louis Dubeau 13  | Nicola MacDonald 14 | Davor Jurkovic 3 | Nora Pashayan 15 | Martin Widschwendter 1,2,3,11,16   \nCorrespondence  \nMartin Widschwendter, European Translational Oncology Prevention and Screening (EUTOPS) Institute, Milser Str.  \n10, 6060 Hall, Austria or Department of Women's Cancer, University College London, Medical School Building, Room  \n340, 74 Huntley Street, London, WC1E 6AU, UK.  \n[Email:](Email: martin.widschwendter@uibk.ac.at)[ martin.widschwendter@uibk.ac.at](Email: martin.widschwendter@uibk.ac.at) and [m.widschwendter@ucl.ac.uk](m.widschwendter@ucl.ac.uk)  \nFunding information  \nThe Eve Appeal; Land Tirol; Horizon 2020 Framework Programme, Grant/Award Number: 634570; European Research Council, Grant/Award Number: 742432; Standortagentur Tirol  \nAbstract  \nThe DNA methylation-based WID-qEC test, applied to cervico-vaginal samples, has been validated for the accurate detection of endometrial and cervical cancers. However, a small proportion of women test positive despite the absence of these cancers. The aim of this study was to explore the biological and clinical characteristics associated with such WID-qEC-positive cases to inform potential follow-up strategies. We analyzed 1269 cervico-vaginal samples from women without endometrial or cervical cancer, including healthy controls (n = 624), women with benign gynecological conditions (n = 324), and ovarian cancer cases (n = 321) . Of the 80 WID-qEC-positive results, 43 (54%) were from women with ovarian cancer. WID-qEC positivity was associated with the presence of ovarian cancer (adjusted odds ratio [OR] 2.93; 95% CI 1.75–4.95) and with a higher number of lifetime ovulatory cycles (adjusted OR 2. 67; 95% CI 1 .06–7. 50), a known ovarian cancer risk factor. Both associations were independent of age, menopausal status, hormone replacement therapy usage, or family history of breast or ovarian cancer. Our findings suggest that in the absence of endometrial or cervical cancer, WID-qEC positivity may indicate an elevated risk or presence of ovarian cancer. While the standalone positive predictive value (PPV) for ovarian cancer detection remains low in the general population, we outline how  \nAbbreviations: AUB, abnormal uterine bleeding; AUC, area under the curve; BMI, body mass index; CC, cervical cancer; CI, confidence interval; Copan, FLOQswab combined with eNAT collection fluid; EC, endometrial cancer; FORECEE, Female cancer predictiOn using ceRvical omics to individualisE sCreEning and prEvention; ML, MethyLight; OC, ovarian cancer; OR, odds ratio; PMR, percentage of fully methylated reference; PPV, positive predictive value; QC, quality control; RT, room temperature; SIR, standardized incidence ratio; ThinPrep, Cervex brush combined with PreservCyt collection fluid; WID-qEC, women's cancer risk identification—quantitative polymerase chain reaction test for endometrial cancer.  \nElisa Redl, Chiara Herzog, and Charlotte Vavourakis contributed equally to this study.  \nFor affiliations refer to page 2535  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n© 2026 The Author(s) . International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.  \nWID-qEC could be used in a two-step triage approach. In women presenting with abnormal bleeding, combining WID","cbCaiph1L237XXi4","https://ap.wps.com/l/cbCaiph1L237XXi4","pdf",702991,"English","# Abstract\n## Study aim and rationale\n## Methods and cohort composition\n## Key findings and statistical associations\n## Clinical implications and triage concept\n# Introduction","[{\"question\":\"Why was this study conducted on WID-qEC-positive women without endometrial or cervical cancer?\",\"answer\":\"Because a small proportion of women test positive with WID-qEC despite having no endometrial or cervical cancers, prompting investigation of associated biological and clinical characteristics.\"},{\"question\":\"What samples and groups were analyzed in the study?\",\"answer\":\"The study analyzed 1269 cervico-vaginal samples from women without endometrial or cervical cancer, including healthy controls, women with benign gynecological conditions, and ovarian cancer cases.\"},{\"question\":\"What factors were associated with WID-qEC positivity in the absence of endometrial or cervical cancer?\",\"answer\":\"WID-qEC positivity was associated with ovarian cancer and with a higher number of lifetime ovulatory cycles, and these associations were independent of age, menopausal status, hormone replacement therapy usage, and family history.\"}]","The cervico-vaginal DNA methylation WID-qEC test - An epigenetic marker associated with ovarian cancer in the absence of endometrial and cervical cancer - Short report | PDF",1790055930,18,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2a635f9cebea5cbf604a5dca71b7e513.webp",983,1291,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/262f77ed1607a2cb0bb80d7e1f136707.webp",982,1290,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fa5b31ac7d8036eb2e0aee336f79bd7d.webp",981,1289,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5ae638af9f476dd098be5a547a44c32f.webp",980,1287]